A corporation that operates under the ticker symbol “LNTH” on the NASDAQ stock market manages this undertaking. The investment analysts at SVB Leerink raised their profit forecasts for the fiscal year 2022 for the shares of Lantheus in a research note published on Friday, January 20th. According to the projections of R. Ruiz, an analyst at SVB Leerink, the medical equipment supplier will earn $3.52 per share in 2018, an increase from his previous projection of $3.51 per share. Analysts at the firm have recently given the stock of SVB Leerink an “outperform” rating. The market anticipates Lantheus to report full-year earnings of $3.53 per share, which is based on the market’s most recent predictions. In addition, the analysts at SVB Leerink anticipate that Lantheus will have earnings per share of $0.89 in the fourth quarter of 2022.
Several other research companies have also very recently published reports on LNTH, most of which have been made available recently. In a report released on October 6th, a Thursday, JonesTrading began providing coverage of shares of Lantheus. They suggested that investors purchase company shares for $104.00 per share as the price objective. StockNews.com changed their recommendation for Lantheus from “hold” to “buy” in a research note published on November 4th, indicating that they now recommend purchasing the stock. The previous recommendation was “hold.”
Last but not least, on October 12th, a research note written by Mizuho and published in their newsletter began covering shares of Lantheus. They suggested making a “buy” investment in the company and established a price target of $105.00 for the stock. According to the information provided by Bloomberg, six different equity research professionals have recommended that investors purchase the stock. These recommendations have been provided as a recommendation to buy the stock. The stock has been assigned a “buy” rating across the board, and market watchers forecast its price will eventually settle at an average of $102.80 per share.
On Monday, trading on the NASDAQ LNTH started at $53.42, lasting until the day’s end. The price of Lantheus has ranged between the low point of $23.51 and the high point of $87.47 over the last 52 weeks. A debt-to-equity ratio comes in at 0.24; a quick ratio comes in at 1.98; a current ratio comes in at 2.13; and a quick ratio comes in at 1.98. The enterprise has a price-to-earnings ratio of 35.85, a beta value of 0.78, and a market capitalization of $3.68 billionLantheus has ranged between the low point of $23.51 and the high point of $87.47 over the last 52 weeks. A debt-to-equity ratio comes in at 0.24; a quick ratio comes in at 1.98; a current ratio comes in at 2.13; and a quick ratio comes in at 1.98. The enterprise has a price-to-earnings ratio of 35.85, a beta value of 0.78, and a market capitalization of $3.68 billion. The stock’s moving averages for the past 50 and 200 days are currently at $54.09 and $66.92, respectively.
The most recent quarterly earnings report for Lantheus was released on November 3rd, and it can be found under the symbol NASDAQ: LNTH on the NASDAQ stock market. Earnings per share (EPS) for the quarter were reported to be $0.90 by the medical equipment manufacturer, which is $0.15 higher than the consensus estimate of $0.75 among industry analysts. Polling industry professionals determined the consensus estimate. The return on equity for Lantheus was calculated to be 37.77%, while the net margin for the company was 13.35%. The company’s sales for the quarter came in at $239.29 million, which was significantly higher than the average expectation of $228.52 million for the quarter’s revenue.
Several institutional investors and hedge funds have recently increased the quantity of LNTH they are currently holding in their portfolios or reduced the quantity they are currently holding. During the second quarter, FinTrust Capital Advisors LLC acquired a new stake in Lantheus by investing approximately $26,000. CWM LLC’s holdings in Lantheus increased 82.1% during the third quarter due to the company’s purchases. CWM LLC now holds 366 shares of the medical equipment provider’s stock, which it obtained by purchasing an additional 165 shares during the period in question. The stock is currently valued at $26,000. During the third quarter, Wipfli Financial Advisors LLC purchased a new position in Lantheus that was estimated to be worth approximately $30,000 at the time of the transaction. During the second quarter, approximately 32,000 dollars were forked over by Dupont Capital Management Corporation to purchase an additional stake in Lantheus. At the end of the third quarter, Focused Wealth Management Inc. had increased its holdings in Lantheus by purchasing additional shares for a total of $63,000, bringing the total amount of money invested in the company to $90,000. The vast majority of the company’s stock (97.62%) is owned by institutional investors who have purchased large blocks of shares.
In related news, Chief Operating Officer Paul Blanchfield sold 2,432 shares of the company’s stock on November 17th. This transaction took place earlier this month. The cost of purchasing all the shares came to a total of $133,249.28, which works out to a price of $54.79 per share on average. After the completion of the transaction, the chief operating officer will have a total of 73,968 shares in the company. Based on the current price of these shares, the chief operating officer will have a net worth of 4,052,706.72 dollars. If you click on this link, you will be taken to a legal filing made with the SEC, which will provide you with additional details about the transaction. Daniel Niedzwiecki, an employee of the company who has inside knowledge, sold 3,000 shares of the company’s stock on November 11th. One of the more recent happenings was this. The shares were sold for a total amount of $179,190.00, which works out to a price of $59.73 per share on average when divided by the total value of the transaction. Following the completion of the sale, the insider will continue to hold a total of 65,143 shares of the company, which will have a combined value of $3,890,991.39 after the transaction. If you click on this link, you will be taken to a legal filing that was made with the SEC, which will give you more information regarding the transaction and take you there immediately. Additionally, on November 17th, Chief Operating Officer Paul Blanchfield sold 2,432 shares of the company’s stock, bringing the total number of shares sold to 2. The cost of purchasing all the shares came to a total of $133,249.28, which works out to a price of $54.79 per share on average. Following the conclusion of the transaction, the chief operating officer will be the owner of 73,968 shares of the company, which have an estimated value of $4,052,706.72 at the time of this writing. Disclosures that are related to the sale might be found in this section of the website. Insiders have sold 19,354 company stock over the past three months, generating $1,105,945 in profits. 1.60 company insiders own a percent of the total shares currently outstanding.
Leave a comment